Since NRF2 controls more than 200 genes and its downregulation can have deleterious effects on normal cells, targeting the specific interactions with proteins that compete with NRF2 for KEAP1 binding might prove to be a more effective strategy of NRF2 downregulation in some cancers. Here, KEAP1 is linked to cancer.